[Peptic diseases]

Rev Med Suisse. 2005 Jan 19;1(3):200-2, 205-8.
[Article in French]

Abstract

The therapeutical acquisitions of the year 2004 are: 1. The sequential treatment of the Helicobacter pylori infection reaches an eradication rate of 95%. 2. The use of COX-2 inhibitors reduced significantly the gastrointestinal side effects of anti-inflammatory treatments. Since cardiac averse effects of certain COX-2 inhibitors had been reported, the treatments with COX-2 inhibitors came widely into question. In the case of patients with risk of NSAID induced gastrointestinal toxicity, the alternative is to return to a treatment with non specific NSAID associated to an prophylactic PPI treatment.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Barrett Esophagus / surgery
  • Cyclooxygenase Inhibitors / therapeutic use*
  • Gastroesophageal Reflux / surgery
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori / pathogenicity
  • Humans
  • Stomach Diseases / drug therapy*
  • Stomach Ulcer / etiology
  • Stomach Ulcer / microbiology
  • Stomach Ulcer / prevention & control

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors